StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines provision for Sales Rebates & Returns Charged to Revenue ($M) ($M)

Form 10-Q / 10-K Accrued Sales Rebates Rollforward Note (XBRL)

Latest, FY2025
1,449
Period ended Dec 31, 2025
Change on a year earlier
+43.9%
1,007 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedProvision for Sales Rebates & Returns Charged to Revenue ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,449+43.9%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 20241,007+90.4%Form 10-K (filed 2026-02-26) ↗
FY2023Dec 31, 2023529+187.9%Form 10-K (filed 2026-02-26) ↗
FY2022Dec 31, 2022184+60.1%Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 2021115+626.6%Form 10-K (filed 2023-02-27) ↗
FY2020Dec 31, 202015.8+154.8%Form 10-K (filed 2022-02-28) ↗
FY2019Dec 31, 20196.20-13.9%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 20187.20+80.0%Form 10-K (filed 2020-03-02) ↗
FY2017Dec 31, 20174–Form 10-K (filed 2019-02-28) ↗

Cite this data

StockData. (2026). BeOne Medicines Provision for Sales Rebates & Returns Charged to Revenue ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn_provision

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.